Welcome to our dedicated page for BRII BIOSCIENCES news (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on BRII BIOSCIENCES stock.
Brii Biosciences Limited reports biotechnology developments centered on chronic hepatitis B functional-cure programs and anti-infective assets. Company news commonly covers clinical data from HBV combination studies, including elebsiran, an HBV-targeting siRNA, and BRII-179, a recombinant protein-based HBV immunotherapeutic designed to induce broad B-cell and T-cell immunity.
Updates also address corporate results, intellectual-property rights for BRII-179, regulatory interactions related to HBV development, and partnership activity for infectious-disease candidates. Brii Bio's anti-infective coverage includes BRII-693, also known as soralimixin, and collaboration or licensing activity tied to development and commercialization in Greater China.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Brii Biosciences Limited reported its fiscal year 2022 results, highlighting a revenue increase to RMB51.6 million due to the COVID-19 therapy commercialization in China. The company is focused on advancing its clinical programs for hepatitis B and depression, with Phase 2 trials set for 2023. Financially, R&D expenses decreased by 10.9% to RMB440.6 million, while total comprehensive expense fell by 94.4% to RMB238.5 million. Brii Bio discontinued its COVID-19 antibody program to prioritize its main clinical projects and remains well-funded through 2025.